Pulsed Field Ablation for Atrial Fibrillation

David Schaack; Boris Schmidt; Shota Tohoku; Stefano Bordignon; Lukas Urbanek; Ramin Ebrahimi; Jun Hirokami; Tolga Han Efe; Shaojie Chen; Kr Julian Chun

doi:10.15420/aer.2022.45

Pulsed Field Ablation for Atrial Fibrillation

Arrhythm Electrophysiol Rev. 2023 Apr 14:12:e11. doi: 10.15420/aer.2022.45. eCollection 2023.

Authors

David Schaack¹, Boris Schmidt^{1

2}, Shota Tohoku¹, Stefano Bordignon¹, Lukas Urbanek¹, Ramin Ebrahimi¹, Jun Hirokami¹, Tolga Han Efe¹, Shaojie Chen^{1

3}, Kr Julian Chun^{1

3}

Affiliations

¹ Cardioangiologisches Centrum Bethanien, Frankfurt, Germany.
² Universitätsklinikum Frankfurt, Medizinische Klinik 3 - Klinik für Kardiologie, Frankfurt, Germany.
³ Die Sektion Medizin, Universität zu Lübeck, Lübeck, Germany.

Abstract

Catheter ablation is a widely used, effective and safe treatment for AF. Pulsed field ablation (PFA), as a novel energy source for cardiac ablation, has been shown to be tissue selective and is expected to decrease damage to non-cardiac tissue while providing high efficacy in pulmonary vein isolation. The FARAPULSE ablation system (Boston Scientific) follows the idea of single-shot ablation and is the first device approved for clinical use in Europe. Since its approval, multiple high-volume centres have performed increasing numbers of PFA procedures in patients with AF and have published their experiences. This review summarises the current clinical experience regarding the use of PFA for AF using the FARAPULSE system. It provides an overview of its efficacy and safety.

Keywords: AF; catheter ablation; pulmonary vein isolation; pulsed field ablation; review.

Publication types

Review